Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 we » 2 e (Expand Search), 2 de (Expand Search), _ we (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 we » 2 e (Expand Search), 2 de (Expand Search), _ we (Expand Search)
-
1841
-
1842
-
1843
-
1844
Risk of bias of the included studies.
Published 2024“…Sensitivity analysis showed that overall conclusion was not changed (SMD = -0.8, 95% CI -1.1 to -0.5, p<0.00001; I<sup>2</sup> = 93%; 14 trials; n = 3846). …”
-
1845
Summary of details of the included studies.
Published 2024“…Sensitivity analysis showed that overall conclusion was not changed (SMD = -0.8, 95% CI -1.1 to -0.5, p<0.00001; I<sup>2</sup> = 93%; 14 trials; n = 3846). …”
-
1846
-
1847
-
1848
-
1849
Fig 5 -
Published 2024“…Sensitivity to lactisole sweetness inhibition was correlated with decreased plasma glucose (R<sup>2</sup> = 0.84, p<0.01) when lactisole was added to the OGTT over the whole test (120 minute AUC). …”
-
1850
-
1851
-
1852
-
1853
-
1854
Ovariectomy (OVX) induced decrease in hexokinase expression and activity: prevention by 17β-estradiol.
Published 2013“…<p>A. In female 3×TgAD brains, OVX induced a significant decrease in protein expression of hexokinase 2 (*, P<0.05, bars represent mean value±SEM, n = 5−6), which was partially prevented by E2 treatment. …”
-
1855
-
1856
-
1857
-
1858
-
1859
-
1860
Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera
Published 2023“…After the discovery of a mutation in the Janus kinase 2 (<i>JAK</i>2<sup>V617F</sup>), JAK2 inhibitors have been tested as second-line therapies. …”